Business Desk :
Novo Nordisk – the world’s largest insulin manufacturer signed an agreement to transfer Danish advanced state-of-the-art insulin devices manufacturing technology to Bangladeshi company, Eskayef at a city hotel on Wednesday, says a press release.
A government delegation visited to the Danish Ministry of Health, the Asia House, the European Medicine Agency and Novo Nordisk in Copenhagen, Denmark in February last year with a view to developing the health sector of Bangladesh through public-private-partnership.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given the company experience and capabilities to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries.
Anand Shetty, Managing Director of Novo Nordisk Bangladesh and Simeen Hossain, Managing Director of Eskayef Pharmaceutical Ltd. signed a Memorandum of Understanding (MoU) to set-up local manufacturing of human and modern insulin in cartridges in the presence of Zahid Malik, State Minister for Health and Family Welfare Ministry.
Eskayef has emerged as one of the leading pharmaceutical companies in Bangladesh. The state-of-the-art manufacturing facility of Eskayef has been approved by stringent global regulators including UK MHRA, European Medicines Agency, TGA Australia, VMD UK and UNICEF. Eskayef is growing globally and are already exporting their products to different countries in Asia, Africa, Europe and Australia.
Zahid Malik, State Minister for Health and Family Welfare Ministry, said: “Diabetes, one of the non-communicable diseases, poses a big threat to sustainable development. The growing number of patients living with diabetes is in constant need of proper care and timely treatment including the need for quality insulin supply at affordable price.”
“The partnership between Novo Nordisk and Eskayef will benefit all patients living with diabetes in Bangladesh. It will help the government to achieve the sustainable development goals by 2030 as set by the United Nations, the Minister said.
“As part of our continuous commitment for people living with diabetes in Bangladesh for more than 60 years, we have decided to set-up local manufacturing of insulin for advanced pens in partnership with our trusted partner Eskayef,” said Sebnem Avsar Tuna, Corporate Vice-President for Novo Nordisk’s Business Area Oceania and South East Asia.
Speaking on the occasion, Latifur Rahman, chairman, Transcom Group said: “The Danish state-of-the-art modern insulin manufacturing technology transfer is a matter of pride, not only for Eskayef but for the whole country. It has only been made possible due to Eskayef’s proven track record of strict adherence to quality. This technology transfer will help the people of Bangladesh in their fight against diabetes with world’s best Insulin products manufactured right here in our own country.”
“The partnership will further strengthen the bilateral relation between Denmark and Bangladesh. It is a historic event and Denmark is proud to be a partner and contribute to the advancement of this sector in Bangladesh,” said the Danish Ambassador to Bangladesh Mikael Hemniti Winther.
Major General Dr. Md. Mustafizur Rahman, Director General of Directorate General of Drug Administration said the joint venture is the reflection of DGDA’s effort to bring high technology to the country for insulin production.
Lars Bo Smidt, Corporate Vice-President, Finance and Operations for Novo Nordisk’s Africa, Asia, Middle East and Oceania regions; S. M. Shafiuzzaman, General Secretary, Bangladesh Association of Pharmaceutical Industries; Kazi M. Aminul Islam, Executive Chairman, Bangladesh Investment Development Authority; Professor AK Azad Khan, President of Diabetic Association of Bangladesh and Roxana Quader, Additional Secretary (Public Health and World health Organization), Ministry of Health and Family Welfare were present at the programme.
Transcom Distribution Company Limited (TDCL) distributes the Novo Nordisk’s insulin products across the country. In fact, it can supply the insulin within two hours anywhere in the country.
Novo Nordisk – the world’s largest insulin manufacturer signed an agreement to transfer Danish advanced state-of-the-art insulin devices manufacturing technology to Bangladeshi company, Eskayef at a city hotel on Wednesday, says a press release.
A government delegation visited to the Danish Ministry of Health, the Asia House, the European Medicine Agency and Novo Nordisk in Copenhagen, Denmark in February last year with a view to developing the health sector of Bangladesh through public-private-partnership.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given the company experience and capabilities to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries.
Anand Shetty, Managing Director of Novo Nordisk Bangladesh and Simeen Hossain, Managing Director of Eskayef Pharmaceutical Ltd. signed a Memorandum of Understanding (MoU) to set-up local manufacturing of human and modern insulin in cartridges in the presence of Zahid Malik, State Minister for Health and Family Welfare Ministry.
Eskayef has emerged as one of the leading pharmaceutical companies in Bangladesh. The state-of-the-art manufacturing facility of Eskayef has been approved by stringent global regulators including UK MHRA, European Medicines Agency, TGA Australia, VMD UK and UNICEF. Eskayef is growing globally and are already exporting their products to different countries in Asia, Africa, Europe and Australia.
Zahid Malik, State Minister for Health and Family Welfare Ministry, said: “Diabetes, one of the non-communicable diseases, poses a big threat to sustainable development. The growing number of patients living with diabetes is in constant need of proper care and timely treatment including the need for quality insulin supply at affordable price.”
“The partnership between Novo Nordisk and Eskayef will benefit all patients living with diabetes in Bangladesh. It will help the government to achieve the sustainable development goals by 2030 as set by the United Nations, the Minister said.
“As part of our continuous commitment for people living with diabetes in Bangladesh for more than 60 years, we have decided to set-up local manufacturing of insulin for advanced pens in partnership with our trusted partner Eskayef,” said Sebnem Avsar Tuna, Corporate Vice-President for Novo Nordisk’s Business Area Oceania and South East Asia.
Speaking on the occasion, Latifur Rahman, chairman, Transcom Group said: “The Danish state-of-the-art modern insulin manufacturing technology transfer is a matter of pride, not only for Eskayef but for the whole country. It has only been made possible due to Eskayef’s proven track record of strict adherence to quality. This technology transfer will help the people of Bangladesh in their fight against diabetes with world’s best Insulin products manufactured right here in our own country.”
“The partnership will further strengthen the bilateral relation between Denmark and Bangladesh. It is a historic event and Denmark is proud to be a partner and contribute to the advancement of this sector in Bangladesh,” said the Danish Ambassador to Bangladesh Mikael Hemniti Winther.
Major General Dr. Md. Mustafizur Rahman, Director General of Directorate General of Drug Administration said the joint venture is the reflection of DGDA’s effort to bring high technology to the country for insulin production.
Lars Bo Smidt, Corporate Vice-President, Finance and Operations for Novo Nordisk’s Africa, Asia, Middle East and Oceania regions; S. M. Shafiuzzaman, General Secretary, Bangladesh Association of Pharmaceutical Industries; Kazi M. Aminul Islam, Executive Chairman, Bangladesh Investment Development Authority; Professor AK Azad Khan, President of Diabetic Association of Bangladesh and Roxana Quader, Additional Secretary (Public Health and World health Organization), Ministry of Health and Family Welfare were present at the programme.
Transcom Distribution Company Limited (TDCL) distributes the Novo Nordisk’s insulin products across the country. In fact, it can supply the insulin within two hours anywhere in the country.
